Developing treatments for patients with underserved CNS disorders
Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (“CNS”) disorders.
Targeting Distinct CNS Conditions with Neurotransmitter Imbalance
Bionomics has a pipeline of novel therapeutic candidates targeting the treatment of serious central nervous system disorders for which there is a large unmet medical need.
Development of our pipeline is accelerated through our partnering strategy, which allows multiple and diverse programs to be optimally developed.